Exopharm Management
Management criteria checks 3/4
Exopharm's CEO is Ian Dixon, appointed in Jan 2020, has a tenure of 3.92 years. total yearly compensation is A$361.79K, comprised of 89.8% salary and 10.2% bonuses, including company stock and options. directly owns 6.43% of the company’s shares, worth A$310.84K. The average tenure of the management team and the board of directors is 2.9 years and 0.8 years respectively.
Key information
Ian Dixon
Chief executive officer
AU$361.8k
Total compensation
| CEO salary percentage | 89.8% |
| CEO tenure | 3.9yrs |
| CEO ownership | 6.4% |
| Management average tenure | 2.9yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Will Exopharm (ASX:EX1) Spend Its Cash Wisely?
May 27
Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Oct 20Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Jul 02Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Apr 03Shareholders Are Thrilled That The Exopharm (ASX:EX1) Share Price Increased 188%
Feb 09
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | AU$362k | AU$325k | -AU$7m |
| Mar 31 2023 | n/a | n/a | -AU$7m |
| Dec 31 2022 | n/a | n/a | -AU$7m |
| Sep 30 2022 | n/a | n/a | -AU$9m |
| Jun 30 2022 | AU$431k | AU$398k | -AU$10m |
| Mar 31 2022 | n/a | n/a | -AU$10m |
| Dec 31 2021 | n/a | n/a | -AU$10m |
| Sep 30 2021 | n/a | n/a | -AU$9m |
| Jun 30 2021 | AU$532k | AU$314k | -AU$8m |
| Mar 31 2021 | n/a | n/a | -AU$8m |
| Dec 31 2020 | n/a | n/a | -AU$7m |
| Sep 30 2020 | n/a | n/a | -AU$6m |
| Jun 30 2020 | AU$255k | AU$233k | -AU$5m |
| Mar 31 2020 | n/a | n/a | -AU$5m |
| Dec 31 2019 | n/a | n/a | -AU$5m |
| Sep 30 2019 | n/a | n/a | -AU$4m |
| Jun 30 2019 | AU$198k | AU$181k | -AU$2m |
| Jun 30 2018 | AU$25k | AU$23k | -AU$175k |
Compensation vs Market: Ian's total compensation ($USD246.59K) is about average for companies of similar size in the Australian market ($USD300.74K).
Compensation vs Earnings: Ian's compensation has been consistent with company performance over the past year.
CEO
Ian Dixon
3.9yrs
Tenure
AU$361,794
Compensation
Dr. Ian E. Dixon, PhD, MBA, MAICD, serves as its Chief Executive Officer and is Company Founder and Technology Co-Founder of Exopharm Limited and has been its Managing Director and Director since 2020. Dr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 3.9yrs | AU$361.79k | 6.43% A$ 310.8k | |
| Co-Founder & Business Services Manager | 2.9yrs | AU$238.48k | no data | |
| Senior Vice President of Finance | no data | no data | no data | |
| Company Secretary | 2.3yrs | no data | no data |
2.9yrs
Average Tenure
Experienced Management: EX1's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 3.9yrs | AU$361.79k | 6.43% A$ 310.8k | |
| Independent Non-Executive Chairman of the Board | less than a year | AU$1.59k | no data | |
| Member of Scientific Advisory Board | no data | AU$22.47k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | less than a year | AU$9.46k | 0.0046% A$ 219.9 |
0.8yrs
Average Tenure
Experienced Board: EX1's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.